AF company Cardima raises $4.5 million for Revelation:
This article was originally published in Clinica
Executive Summary
Cardima, which has developed the linear ablation system, Revelation Tx, for the treatment of atrial fibrillation, has completed a $4.5m private placement. The Fremont, California-based company plans to submit a premarket approval application for its product to the FDA this quarter. Atrial fibrillation, which affects some two million Americans and 4.5 million people worldwide, is believed to represent a potential $6bn market that is underserved by existing methods, Cardima says.